| First Author | Battaglin F | Year | 2021 |
| Journal | Oncogene | Volume | 40 |
| Issue | 18 | Pages | 3187-3200 |
| PubMed ID | 33846572 | Mgi Jnum | J:305482 |
| Mgi Id | MGI:6706371 | Doi | 10.1038/s41388-021-01778-6 |
| Citation | Battaglin F, et al. (2021) Clocking cancer: the circadian clock as a target in cancer therapy. Oncogene 40(18):3187-3200 |
| abstractText | Disruption of the cellular pathway modulating endogenous 24-h rhythms, referred to as "the circadian clock", has been recently proven to be associated with cancer risk, development, and progression. This pathway operates through a complex network of transcription-translation feedback loops generated by a set of interplaying proteins. The expression of core circadian clock genes is frequently dysregulated in human tumors; however, the specific effects and underlying mechanisms seem to vary depending on the cancer types and are not fully understood. In addition, specific oncogenes may differentially induce the dysregulation of the circadian clock in tumors. Pharmacological modulation of clock components has been shown to result in specific lethality in certain types of cancer cells, and thus holds great promise as a novel anti-cancer therapeutic approach. Here we present an overview of the rationale and current evidence for targeting the clock in cancer treatment. |
